NCT07096024View on ClinicalTrials.gov

A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market

CompletedOBSERVATIONAL
Enrollment

1,772

Participants

Timeline

Start Date

January 21, 2025

Primary Completion Date

February 7, 2025

Study Completion Date

February 7, 2025

Conditions
Breast Neoplasms
Interventions
DRUG

palbociclib plus fulvestrant

Patients treated with the combination of palbociclib and fulvestrant

DRUG

fulvestrant

Patients treated with fulvestrant alone

Trial Locations (1)

10001

Pfizer New York, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT07096024 - A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market | Biotech Hunter | Biotech Hunter